UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have been assigned an average rating of “Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $43.70.

Separately, D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Tuesday.

Insider Buying and Selling

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.

Institutional Trading of UroGen Pharma

A number of institutional investors and hedge funds have recently modified their holdings of URGN. SG Americas Securities LLC purchased a new stake in UroGen Pharma during the 3rd quarter valued at about $179,000. China Universal Asset Management Co. Ltd. increased its position in UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after purchasing an additional 3,856 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in UroGen Pharma by 273.6% in the 3rd quarter. Rice Hall James & Associates LLC now owns 271,897 shares of the company’s stock valued at $3,453,000 after purchasing an additional 199,110 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of UroGen Pharma during the 3rd quarter valued at approximately $249,000. Finally, Intech Investment Management LLC purchased a new position in UroGen Pharma in the third quarter worth approximately $155,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Stock Down 1.9 %

URGN stock opened at $10.56 on Wednesday. The company has a market cap of $247.63 million, a price-to-earnings ratio of -3.35 and a beta of 1.08. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The business’s 50-day moving average is $10.79 and its two-hundred day moving average is $12.26. UroGen Pharma has a fifty-two week low of $9.78 and a fifty-two week high of $20.70.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.